Processing

Please wait...

Settings

Settings

1. WO2000042856 - ACTIVATION OF REGULATORY T CELLS BY ALPHA-MELANOCYTE STIMULATING HORMONE

Publication Number WO/2000/042856
Publication Date 27.07.2000
International Application No. PCT/US2000/001608
International Filing Date 21.01.2000
Chapter 2 Demand Filed 09.08.2000
IPC
C12N 15/09 2006.01
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
15Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
09Recombinant DNA-technology
A61K 35/14 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
14Blood; Artificial blood
A61K 38/34 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
33derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
34Melanocyte stimulating hormone , e.g. alpha- or beta-melanotropin
A61K 39/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
A61K 48/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
48Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
A61P 29/00 2006.01
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
29Non-central analgesic, antipyretic or antiinflammatory agents, e.g antirheumatic agents; Non-steroidal antiinflammatory drugs (NSAIDs)
CPC
A61K 2035/122
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
35Medicinal preparations containing materials or reaction products thereof with undetermined constitution
12Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
122for inducing tolerance or supression of immune responses
A61K 38/34
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
38Medicinal preparations containing peptides
16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
17from animals; from humans
33derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
34Melanocyte stimulating hormone [MSH], e.g. alpha- or beta-melanotropin
A61K 39/0008
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
39Medicinal preparations containing antigens or antibodies
0005Vertebrate antigens
0008Antigens related to auto-immune diseases; Preparations to induce self-tolerance
C12N 2500/90
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2500Specific components of cell culture medium
90Serum-free medium, which may still contain naturally-sourced components
C12N 2501/15
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2501Active agents used in cell culture processes, e.g. differentation
10Growth factors
15Transforming growth factor beta (TGF-β)
C12N 2501/515
CCHEMISTRY; METALLURGY
12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
2501Active agents used in cell culture processes, e.g. differentation
50Cell markers; Cell surface determinants
515CD3, T-cell receptor complex
Applicants
  • THE SCHEPENS EYE RESEARCH INSTITUTE, INC. [US/US]; 20 Staniford Street Boston, MA 02114, US (AllExceptUS)
  • TAYLOR, Andrew, W. [US/US]; US (UsOnly)
  • NISHIDA, Tomomi [JP/JP]; JP (UsOnly)
Inventors
  • TAYLOR, Andrew, W.; US
  • NISHIDA, Tomomi; JP
Agents
  • YIP, Gwendolyn, H. ; Weingarten, Schurgin, Gagnebin & Hayes LLP Ten Post Office Square Boston, MA 02109, US
Priority Data
60/116,85122.01.1999US
60/156,78830.09.1999US
Publication Language English (EN)
Filing Language English (EN)
Designated States
Title
(EN) ACTIVATION OF REGULATORY T CELLS BY ALPHA-MELANOCYTE STIMULATING HORMONE
(FR) ACTIVATION DE LYMPHOCYTES T REGULATEURS PAR UNE HORMONE STIMULANT DES ALPHA-MELANOCYTES
Abstract
(EN)
The invention encompasses a method of down-regulating a T cell-mediated immune response, through activation or T cell receptor (TCR) stimulation of antigen-primed T cells in the presence of alpha-melanocyte stimulating hormone ($g(a)-MSH), which may be optionally enhanced by adding transforming growth factor-$g(b)2 (TGF-$g(b)2) approximately 4-6 hours after the start of the primed T cells' exposure to $g(a)-MSH. Activation of the primed T cells may be mediated by presentation of the specific antigen to the primed T cells, or by an anti-TCR antibody or a T cell mitogen. As a result of the $g(a)-MSH treatment modulating the T cell activation, antigen-specific, regulatory, CD4+/CD25+ T cells are generated that produce transforming growth factor-$g(b) (TGF-$g(b)) and can non-specifically down-regulate Th1-mediated inflammatory activities. The method may be used to down-regulate or suppress an autoimmune condition or a graft rejection in a transplant patient. The invention also encompasses a kit for generating regulatory T cell comprising a speciric antigen, $g(a)-MSH, and optionally, TGF-$g(b)2 and/or a T cell culture medium. Also provided are gene therapy treatments for suppressing an autoimmune or graft rejection response, or for re-establishing autotolerance, by introducing genetic material (e.g. nucleic acid) for expressing $g(a)-MSH or a receptor-binding portion thereof, into a localized tissue site.
(FR)
Cette invention concerne une méthode assurant la régulation négative d'une réponse immunitaire médiée par les lymphocytes T par activation ou stimulation, via les récepteurs des lymphocytes T (TRC), de lymphocytes T mémoires spécifiques d'antigène en présence de l'hormone mélanotrope alpha ($g(a)-MSH), ce qui peut éventuellement être accentué par l'adjonction du facteur-$g(b)2 (TGF$g(b)2) de transformation cellulaire 4 à 6 heures après le début de l'exposition du lymphocyte T mémoire à l'$g(a)-MSH. On peut déclencher l'activation des lymphocytes T spécifiques d'antigène en leur présentant l'antigène spécifique, ou au moyen d'un anticorps anti-TRC ou d'un mitogène de lymphocyte T. Le traitement par l'$g(a)-MSH qui module l'activation des lymphocytes T a pour effet de générer des lymphocytes T CD41/CD25+, spécifiques d'antigène, régulateurs, qui produisent un facteur-$g(b) (TGF-$g(b) de transformation cellulaire et peuvent assurer une régulation négative non spécifique des activités inflammatoires médiées par les Th-1. Cette méthode peut être utilisé pour obtenir une régulation négative ou bien pour supprimer une pathologie auto-immune ou éviter un rejet de greffe chez un sujet greffé. Cette invention concerne également un kit permettant de générer des lymphocytes T régulateurs renfermant un antigène spécifique, $g(a)-MSH, et, éventuellement, TGF-$g(b)2 et/ou un milieu de culture de lymphocytes T. De plus, l'invention concerne des thérapies géniques permettant de lutter contre des réponses autoimmunes ou des rejets de greffe, ou bien de rétablir une autotolérance en introduisant. dans un site tissulaire localisé, un matériau génétique (tel qu'un acide nucléique) afin d'exprimer $g(a)-MSH ou une partie d'$g(a)-MSH se liant à un récepteur.
Also published as
US09912670
Latest bibliographic data on file with the International Bureau